Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”
This article was originally published in The Gray Sheet
Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.
You may also be interested in...
Tandem Diabetes Care’s t:slim G4 insulin pump/continuous glucose monitor system is the latest DexCom partnership to yield an FDA approval, and the first integrated diabetes system to feature a touch-screen display.
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
The single-arm pivotal trial is assessing the firm's next-generation diabetes system, which adds predictive algorithm features and a smaller sensor compared to the currently marketed MiniMed 530G low-glucose suspend device, marking another step towards an artificial pancreas, Medtronic says.